---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-004713"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2021-11-17T23:59:59+00:00"
generated_at: "2026-06-28T07:35:22.773679+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sarepta appoints Stephen Mayo to board, promotes Rodino-Klapac to R&D head, O'Neill departs

## Summary
- Stephen L. Mayo appointed to Sarepta board, effective Nov 16, 2021; receives $712,500 equity grant split between RSUs and options plus $50k annual cash.
- Louise Rodino-Klapac promoted to Head of R&D, Chief Scientific Officer; granted 40,000 RSUs vesting 25% annually over 4 years.
- Gilmore O'Neill mutually agreed to end employment effective Nov 30, 2021; will serve as consultant through Q1 2022.
- Outstanding equity awards issued to O'Neill continue to vest during the consulting period.

## SEC filing metadata
- accession: 0000950170-21-004713
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2021-11-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/0000950170-21-004713-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/srpt-20211115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-004713
- JSON: https://secwatch.observer/filing/0000950170-21-004713.json
- Plain text: https://secwatch.observer/filing/0000950170-21-004713.txt

## Key facts
- Executive change
  Gilmore O'Neill resigned as other_named_officer at Sarepta Therapeutics, Inc..
  - Action: resigned
  source text: On November 15, 2021, the Company and Gilmore O’Neill, M.B., M.M.Sc. mutually agreed to end Dr. O'Neill's employment with the Company, effective as of November 30, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/0000950170-21-004713-index.htm
- Executive change
  Stephen L. Mayo was appointed as Director at Sarepta Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 16, 2021, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the "Company") appointed Stephen L. Mayo, Ph.D. as a director of the Company, effective as of November 16, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/0000950170-21-004713-index.htm
- Executive change
  Louise Rodino-Klapac changed role as Head of R&D, Chief Scientific Officer at Sarepta Therapeutics, Inc..
  - Action: promoted
  - Role: Head of R&D, Chief Scientific Officer
  source text: On November 16, 2021, Louise Rodino-Klapac, Ph.D., the Company's Chief Scientific Officer, was promoted to Head of R&D, Chief Scientific Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/0000950170-21-004713-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.